Systematic review of piperacillin-induced neutropenia

Drug Safety

Volumn 30, Issue 4, 2007, Pages 295-306

  Scheetz, Marc H ^a   McKoy, June M ^b,c   Parada, Jorge P ^d   Djulbegovic, Benjamin ^e   Raisch, Dennis W ^f   Yarnold, Paul R ^c   Zagory, Jessica ^b   Trifilio, Steve ^a   Jakiche, Rita ^f   Palella, Frank ^c   Kahn, Adam ^b   Chandler, Kevin ^b   Bennett, Charles L ^b,c,g  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZITHROMYCIN; AZTREONAM; CEFAZOLIN; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; FLUCONAZOLE; FUROSEMIDE; GENTAMICIN; METRONIDAZOLE; MEZLOCILLIN; NAFCILLIN; OMEPRAZOLE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; STREPTOKINASE; TAZOBACTAM; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ABSCESS; AGRANULOCYTOSIS; BLOOD TOXICITY; BONE INFECTION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYSTIC FIBROSIS; DATA BASE; DEMOGRAPHY; DOSE RESPONSE; FATALITY; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GRANULOCYTOPENIA; HOSPITALIZATION COST; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; META ANALYSIS; NEUTROPENIA; OSTEOMYELITIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; URINARY TRACT INFECTION;

EID: 34247231036     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730040-00002     Document Type: Review

References (22)

1. Neftel KA, Hauser SP, Muller MR. Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics. J Infect Dis 1985; 152 (1): 90-8
2. Spain D, Clark T. A case of agranulocytosis occurring during the course of penicillin therapy. Ann Intern Med 1946 (25): 732-3
3. Singh N, Yu VL, Mieles LA, et al. Beta-Lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease. Am J Med 1993; 94 (3): 251-6
4. Olaison L, Alestig K. A prospective study of neutropenia induced by high doses of beta-lactam antibiotics. J Antimicrob Chemother 1990; 25 (3): 449-53
5. Behbahani R, Kostman JR. Hypersensitivity reaction during prolonged use of piperacillin/tazobactam in treatment of osteomyelitis. Ann Pharmacother 1995; 29 (9): 936-7
6. Gerber L, Wing EJ. Life-threatening neutropenia secondary to piperacillin/tazobactam therapy. Clin Infect Dis 1995; 21 (4): 1047-8
7. Kirkwood CF, Lasezkay GM. Neutropenia associated with mezlocillin and piperacillin. Drug Intell Clin Pharm 1985; 19 (2): 112-4
8. Kumar A, Choudhuri G, Aggarwal R. Piperacillin induced bone marrow suppression: a case report. BMC Clin Pharmacol 2003; 3 (1): 2
9. Rye PJ, Roberts G, Staugas RE, et al. Coagulopathy with piperacillin administration in cystic fibrosis: two case reports. J Paediatr Child Health 1994; 30 (3): 278-9
10. Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol 1996; 95 (4): 611-2
11. Wilson C, Greenhood G, Remington JS, et al. Neutropenia after consecutive treatment courses with nafcillin and piperacillin. Lancet 1979; 1 (8126): 1150
12. Peralta FG, Sanchez MB, Roiz MP, et al. Incidence of neutrope nia during treatment of bone-related infections with piperacillin-tazobactam. Clin Infect Dis 2003; 37 (11): 1568-72
13. Khan F. Severe nuetropenia secondary to piperacillin/ tazobactam therapy. Indian J Pharmacol 2005; 37: 192-3
14. Zosyn® (Piperacillin and tazobactam) [product information]. Philadelphia (PA): Wyeth Pharmaceuticals, Oct 2005
15. Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA 2005; 293 (17): 2131-40
16. Kjaeldgaard P, Arffmann S, Heilesen AM. Bone marrow function after treatment with piperacillin (Ivacin) and tobramycin (Nebcina) [in Danish]. Ugeskr Laeger 1987; 149 (37): 2470
17. Sugimoto M, Wakabayashi Y, Shiokawa Y. A case of piperacillin induced leucopenia whose CFU-C derived colony was inhibited in vitro by the coexisting addition of drug, serum, and mononuclear cells [in Japanese]. Rinsho Ketsueki 1984; 25 (2): 197-202
18. Lang R, Lishner M, Ravid M. Adverse reactions to prolonged treatment with high doses of carbenicillin and ureidopenicillins. Rev Infect Dis 1991; 13 (1): 68-72
19. Reichardt P, Handrick W, Linke A, et al. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment: a retrospective analysis in 38 children with cystic fibrosis. Infection 1999; 27 (6): 355-6
20. Kuye O, Teal J, DeVries VG, et al. Safety profile of piperacillin/ tazobactam in phase I and III clinical studies. J Antimicrob Chemother 1993; 31 Suppl. A: 113-24
21. Wise R. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia. J Antimicrob Chemother 1993; 31 Suppl. A: 97-104
22. Yow MD, Taber LH, Barrett FF, et al. A ten-year assessment of methicillin-associated side effects. Pediatrics 1976; 58 (3): 329-34